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DNA targeting drugs represent a large proportion of the actual anticancer drug pharmacopeia, both in terms of drug brands and
prescription volumes. Small DNA-interacting molecules share the ability of certain proteins to change the DNA helix’s overall
organization and geometrical orientation via tilt, roll, twist, slip, and ﬂip eﬀects. In this ocean of DNA-interacting compounds,
most stabilize both DNA strands and very few display helix-destabilizing properties. These types of DNA-destabilizing eﬀect are
observed with certain mono- or bis-intercalators and DNA alkylating agents (some of which have been or are being developed as
cancer drugs). The formation of locally destabilized DNA portions could interfere with protein/DNA recognition and potentially
aﬀect several crucial cellular processes, such as DNA repair, replication, and transcription. The present paper describes the
molecular basis of DNA destabilization, the cellular impact on protein recognition, and DNA repair processes and the latter’s
relationships with antitumour eﬃcacy.
1.Introduction
The integrity of DNA is an important aspect of cell sur-
vival, since the molecule carries hereditary information and
instructs essential biological processes such as transcription
and replication of living cells. Alteration of this information
can lead to various diseases, including cancer. The various
cancer drugs that have been used in chemotherapy over
the last 60 years kill cells in diﬀerent ways. In addition to
the targeted therapies developed over the last two decades,
many routinely used anticancer agents (topoisomerase I/II
inhibitors, DNA alkylating agents, and antimetabolites)
target the DNA helix itself. The empirical use of alkylating
compounds in cancer treatment started in the 1940s [1].
Watson and Crick’s discovery of the DNA double helix
in 1953 [2] led to extensive research in the ﬁeld of the
interactions between small molecules (whether of natural
or synthetic origin) with nucleic acids. In turn, this work
prompted the widespread use of some of these molecules as
anticancer agents [3–7].
The interaction between small ligands and DNA involves
either (i) nonspeciﬁc binding through electrostatic interac-
tionswiththenegativelychargedsugar-phosphatebackbone,
(ii) intercalation of the ligand’s planar aromatic rings
betweentwoadjacentbasepairs(seeFigure 1),or(iii)major-
or minor-groove binding. Following DNA recognition by
anticancer compounds, the subsequent interaction can
either be noncovalent (DNA ligands) or covalent (alkylating
agents). Whereas most DNA-interacting compounds stabi-
lize the DNA double helix, a few display the particular ability
to destabilize it—leading potentially to various cellular
consequences.
2. To Be or Not to Be a Helix
The DNA double helix is conventionally illustrated as a
spiral staircase, in which the two strands (the handrails)
are stabilized by hydrogen bonds between the Watson-
Crick base pairs (the steps). However, these “steps” are not
stable because their noncovalent interactions are reversible.2 Journal of Nucleic Acids
Depending on the DNA sequence, denaturation (melting)
can be local or widespread [8, 9] and enables various crucial
cellular processes (including DNA replication, transcription,
and repair) to take place [10–12].
Both sequence speciﬁcity and interaction (whether
covalent or not) with a small compound or a protein can
induce tilt, roll, and twist eﬀects (a rotation of the base pairs
in the x, y,o rz axis, respectively—Figure 1) and therefore
change the helix’s overall organization. Furthermore, slide or
ﬂip eﬀects can also modify the geometrical orientation of the
DNA helix (Figure 1). Hence, the ﬂip eﬀect and (to a lesser
extent) the other above-deﬁned movements modulate the
double-strandstability withinthehelixoratitsends. Indeed,
under physiological conditions, local DNA “breathing” has
been evidenced at both ends of the DNA helix [14]a n d
B-to-Z DNA structural transitions have been observed in
internal DNA regions [15] in a sequence-dependent manner
[8, 16–29]. These types of locally open DNA structures are
good substrates for speciﬁc proteins (such as single-strand
binding proteins, SSBPs) which can also induce the opening
of a “closed” DNA helix. In addition to naturally occurring
DNA breathing, the helix can also be unzipped by cellular
proteins and DNA binding compounds (some of which are
used in the clinic).
3.Protein-MediatedUnzipping
In order to achieve essential cellular processes such as DNA
transcription, replication and repair, some cellular proteins
are able to naturally unzip the DNA helix [30]. The most
well known of these (DNA helicases) are essential players
in the above-mentioned processes. The destabilization is
obtained through either an active, direct separation of the
two DNA strands [31–33] or a passive opening mode
in which the helicase binds to the locally single-stranded
DNA portion generated by base pairing ﬂuctuation (which
mostly depends on the DNA sequence and induces prebent
DNA structures) [34–36]. After DNA opening, the helicase
partially translocates to the generated single-stranded DNA
regions and subsequently moves along the base pairs to
unwind the double helix at up to 500–1000bp·s−1. The latter
process requires Mg2+ and ATP [37]. The BLM helicase (the
human RecQ helicase responsible for Bloom’s syndrome,
which is characterized by DNA repair deﬁciencies) actively
destabilizes the DNA duplex and performs rapid, eﬃcient
DNA strand separation [38].
Helicases are not the only proteins with intrinsic
double-strand DNA opening ability; this is also a property
of replication protein A (RPA), a very eﬃcient DNA
destabilizing protein involved in many DNA metabolism
processes (including repair, replication, and recombina-
tion) [39–41]. RPA is a mammalian nuclear SSBP; the
SSBP family members (comprising eukaryotic, bacterial
and viral proteins) can eﬃciently destabilize DNA helix by
unwinding up to one thousand base pairs. Similarly, the
mouse myeloma helix-destabilizing protein, the calf thymus
hnRNP-related protein UP1 and the mammalian P8 protein
(related to glyceraldehyde-3-phosphate-dehydrogenase) also
present both DNA single-strand binding and DNA helix-
destabilizing abilities, as evidenced in thermal denaturation
measurements [42–44].
High-mobility group (HMG) proteins are structurally
and functionally important chromatin components which
also display DNA destabilizing activities. Indeed, melting
studieshaverevealedthatbothHMG1andHMG2destabilize
DNA in the presence of 25 to 100mM NaCl but stabilize
DNA in the absence of salt [45, 46]. An HMG-related DNA
binding domain with DNA-destabilization properties has
been found within c-Abl kinase protein. Moreover, this DNA
destabilization was shown to increase the extent of HMG
protein binding to DNA in the vicinity of the c-Abl binding
site [47, 48].
More recently, it has been reported that the nucleo-
capsid protein of HIV-1 can destabilize DNA [49] via its
DNA-bending activity [50]. More speciﬁcally, the DNA-
destabilization function involves the protein’s ﬁrst zinc ﬁn-
ger, bearing residues Ile24 and Asn27 [51]. Similarly, a DNA
destabilization process was attributed to prion protein. The
latter’s pathological mechanism of action involves translo-
cation to the nucleus, where the protein binds chromatin
and converts to insoluble aggregates. Using FRET-coupled
DNA-melting temperature studies, prion protein was found
to induce signiﬁcant DNA bending, unwinding, and thus
local destabilization of the DNA helix [52].
Althoughtheabove-mentionedproteinsinducerelatively
large DNA destabilization eﬀects, small modiﬁcations (such
as base ﬂipping) could also perturb the local stability of
DNA [53]. Various DNA nucleotide excision repair (NER)
proteins [54, 55], base excision repair proteins [56–61],
and DNA methyltransferases [62, 63] (such as cytosine-
C5-methyltransferase [64]) are known to promote base
ﬂipping. More recently, base ﬂipping has been described in
the recognition of methylated bases by the SET and RING-
associated (SRA)domain protein UHRF-1 [65, 66] and DNA
binding by the transcription factor NF-κB[ 67].
4.DNA Ligand-MediatedUnzipping
Small compounds that interact noncovalently with DNA can
bind to the minor or major groove between the two walls of
the DNA helix, via intercalation between two planar “rungs”
of the base pase staircase (Figure 1) or covalently as a result
of DNA alkylation. Most of the DNA unwinding compounds
with well-deﬁned binding modes belong to the intercalating
or alkylating groups.
Mono- and bis-intercalators present their intercalative
ringsbetweenadjacentbasepairsinparallelorperpendicular
ways. This results in (i) unwinding of the DNA helix by an
angle x◦, where x◦ < 36◦ (since 36◦ is the rotation angle
between two adjacent base pairs in native DNA), and (ii)
subsequent elongation of the DNA (ΔLength). The value of
x◦ depends on the nature of the interacting compound (the
rotated orange arrow in Figure 1).
With DNA alkylating agents, DNA destabilization can
arise from DNA bending, base ﬂipping, or much more
extensive DNA opening (Figure 1).Journal of Nucleic Acids 3
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Figure 1: Schematic representation of DNA structure. (a) Base pair orientation with x, y, and z axes result in diﬀerent kind of rotation (tilt,
roll, twist) or slipping of the bases (slide, ﬂip) regarding to the helix central axis. (b) Native B-DNA with nearly 11 base pairs within one helix
turn. (c) Mono- or bis-intercalation between adjacent base pairs result in an unwinding of the DNA helix (orange arrow on the top) and a
lengthening of the DNA helix (ΔLength) depending on the x◦ and y ˚ A values that are speciﬁc for a deﬁned DNA intercalating compound. (d)
Representation of the DNA bending, base ﬂipping, or double strand opening induced by some DNA destabilizing alkylating agents (adduct).
Adapted from Calladine and Drew’s schematic boxes representation [13].
4.1. DNA Intercalators. DNA-intercalating agents which
impair the stability of the helix can be either mono- or bis-
intercalators.
4.1.1. Monointercalating Compounds. Acridine orange (AO)
(Figure 2) is well known for its ability to intercalate between
double-stranded DNA but can also bind single-stranded
D N Aw i t hh i g ha ﬃnity. When bound to DNA, AO ﬂuoresces
at diﬀerent wavelengths, depending on the nature of the
nucleic acid; green ﬂuorescence occurs after binding to
double-strand DNA, whereas red luminescence results from
interaction with single-strand DNA. Thermal denaturation
studies suggest that the overall stability of the DNA double
helix is increased by AO binding [68]. However, local dis-
tortion and denaturation of double-stranded DNA are also
generated, as evidenced by formaldehyde and diethylpyro-
carbonate(DEPC)probing[69].DNAdenaturationafterAO
binding was also conﬁrmed by spectral and thermodynamic
data [70]a n din situ experiments [71, 72].
Ellipticine and adriamycin (Figure 2) also induce local
unzipping of the DNA helix; the DNA melting temperature
(Tm) falls by 5.1 and 4.8◦C, respectively, [69, 70, 75]. As with4 Journal of Nucleic Acids
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Figure 2: Mono- and bis-intercalating compounds inducing local destabilization of the DNA helix. (a) Structure of the compounds. (b)
Three-dimensional organisation of morpholino doxorubicin bound to d(CGTACG) (left panel) and of ellipticine (right panel) intercalated
between adjacent base pairs (from crystallographic data [mmdbId:52942] and [mmdbId:52189], respectively, [73, 74]).
AO, these two compounds bind eﬃciently to single-stranded
DNA [76, 77]. This contrasts with ethidium bromide’s
binding to nucleic acids, which is highly speciﬁc for double-
stranded DNA and does not destabilize the double helix
[78]. Ellipticine, adriamycin, and AO all intercalate between
two adjacent base pairs and then subsequently change their
orientation to interact with the single-stranded nucleic acid
sections formed locally during DNA breathing. The single-
stranded portions within the DNA helix lengthen because
of cooperative binding by the intercalator, which thus leads
to a higher level of DNA denaturation. This progressive
unzipping of the DNA helix has also been observed in
situ using cytometry, with a direct relationship between
the decrease in green ﬂuorescence and increased concen-
trations of AO in treated cells or nuclei [72]. Furthermore,
post denaturation aggregate formation was observed using
electron microscopy, with DNA condensation occurring
primarily in heterochromatin, ribosomal, and polysomal
structures [71, 72].
4.1.2. Bis-Intercalating Agents. Within the bis-intercalating
group of compounds, the cyclo-bis-intercalator bisacridine A
(BisA)( Figure 2) also displayed DNA unwinding properties.
This macrocyclic compound is composed of two acridine
cores (the DNA-intercalating motifs) linked by polyammo-
nium bridges [79]. By using a variety of complementaryJournal of Nucleic Acids 5
biochemical and biophysical techniques (such as ﬂuores-
cence, melting temperature studies, and gel electrophoresis),
Slama-Schwok et al. nicely demonstrated the ability of the
polyaminomacrocycle BisA to shift the equilibrium from
duplex DNA towards hairpin nucleic acid structures [80]
and to destabilize double-stranded DNA [81]( t w op r o p e r -
ties not observed with monoacridine derivatives). Another
characteristic of BisA is its potent ability to bind single-
stranded DNA. Additionally, when irradiated with light,
BisA eﬃciently induces photocleavage through its acridine
photoactive core. This activity is greater with single-stranded
nucleic acids than with double-stranded nucleic acids [82].
Interestingly, NMR and molecular modelling studies of BisA
compounds bound to an abasic site-containing DNA show
that one acridine ring intercalates between the C·Aa n dT ·G
basepairs,thesecondringliesinthefreespaceofanA·Tbase
pairing and the linker chains are positioned in the major and
minor grooves on each side [83]. On the base-pair level, T·G
mismatches and AP·T recognition result in base ﬂipping of
the thymine—suggesting that BisA sterically prevents DNA
glycosylases from binding to their speciﬁc, base-damaged
recognition sites [84].
4.2. DNA Alkylating Agents. Intercalating agents are
reversible DNA ligands. However, some covalent DNA-
binding anticancer drugs can also locally destabilize the
DNA helix; these include the well-known alkylating agent
cisplatin and its derivatives and the recent drug candidate
S23906-1 (a benzo-acronycine derivative). This contrasts
with the DNA stabilization properties of most DNA-
alkylating agents (whether used in chemotherapy or not),
such as mitomycin C,s o m epsoralen and dinuclear platinum
derivatives,ecteinascidine743andnitrogenmustards[85–91].
4.2.1. Platinated DNA Destabilizing Agents. Cisplatin (cis-
diaminedichloridoplatinum(II); Figure 3) was one of the
ﬁrst chemotherapeutic agents to be developed and is still
frequently used in the clinic. It is able to form inter- and
intrastrand crosslinks and monovalent adducts, primarily
though covalent bonding to the N7 atom of guanine
residues. The most common lesion is the intra-strand
crosslink (occurring preferentially (65%) at the GpG din-
ucleotide), followed by ApG intrastrand crosslinks (25%).
Interstrand crosslinks occur less frequently and depending
on the nature of the platinated agent, with 5 to 8%
for cisplatin, 12% for transplatin (Figure 3)a n du pt o
30% for trans-PtCl2(NH3)(quinoline)( Figure 3)a n dtrans-
PtCl2(NH3)(thiazole) derivatives. In comparison, nitrogen
mustards induce 1 to 5% of inter-strand crosslinks, whereas
nitrosourea and mitomycin C induce 2 to 8% and 5 to
13%, respectively [93–95]. Cisplatin-induced intra-strand
crosslinks at GpG base pairs result in (i) bending of the
DNA axis toward the major groove with an angle of 55–
78◦, and (ii) DNA distortion, enabling local denaturation
of the double helix via destabilization of the Watson-Crick
base pairing [96–102]. In comparison, the bending angle
for inter-strand crosslinks is 45◦ and is associated with
DNA unwinding of 79 ± 4◦. The distortion in platinated-
GpG intra-strand crosslinks is diﬀerent and depends on
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Figure 3: Platinium derivatives. (a) Examples of platinated agents
inducing local destabilization of the DNA helix. (b) The three-
dimensional organization of cisplatin bound to DNA are drawn
from crystallographic data [mmdbId:47796] [92] and evidenced
strong DNA bending induced by cisplatin on a duplex DNA
decamer oligonucleotide that ﬁts with the L-shape angle of HMG-
box DNA-binding domain.
the sequence context, with up to 7bp for 1,3-intrastrand
crosslinks in a TGTGT context [101]. This destabilization
was found to be enthalpic (rather than entropic) in origin
[101, 103]. Similarly, cisplatin adducts occurring at the 5 -
TGGT sequence induce a decrease of more than 10◦Ci n
the melting temperature—much higher than the decrease of
6◦Co rs om e a s u r e df o r5  -CGGT and 5 -AGGC sequences
[104, 105]. DNA stabilization/destabilization also depends
on the pH of the milieu [106]. In contrast to cisplatin,6 Journal of Nucleic Acids
the interstrand crosslinks formed by transplatin do not
destabilize the DNA helix or correlate with changes in the
transition entropy or enthalpy [101, 107].
Interestingly, the third-generation platinum antitu-
mor derivative oxaliplatin [(1R,2R-diamminocyclohexane)-
oxalatoplatinum-(II)](Figure 3)wasfoundto induce greater
DNA unwinding, bending and helix destabilization than
cisplatin. This correlates with the lower degree of cellular
DNA damage seen after oxaliplatin treatment than after
cisplatin treatment and the lower HMG protein aﬃnity
for oxaliplatin-versus cisplatin-induced damage [101]; these
ﬁndingssuggestthatthetwomoleculesinducediﬀerentDNA
repair processes/eﬃciencies, depending on the extent of local
helix destabilization.
It is noteworthy that some other bifunctional platinated
derivatives do not destabilize the DNA duplex. This is the
case for pyrazolato-bridged dinuclear platinum(II) com-
plex [(cis-{Pt(NH3)2})2(mu-OH)(mu-pyrazolate)]2+,w h i c h
crosslinks two adjacent guanines and unwinds the DNA by
around15◦ butdoesnotchangethedirectionalityofthehelix
axis. This absence of bending may explain the lack of DNA
destabilization [108].
The DNA sequence is also important; monofunctional
platinum adducts exhibit diﬀerent DNA destabilizing eﬀects
depending on the base sequences surrounding the guanine
target site [97, 109]. Indeed, when oligonucleotide con-
taining platinum adducts were incubated in the presence
of 50 or 500mM NaCl, the highest DNA destabilization
was observed when the guanine target was located within
the TGC triplet sequence (with a ΔTm value of −10.6◦C
and −13.2◦C, resp.). For all triplets, the decrease in Tm
was greater in 500mM NaCl buﬀe rt h a ni n5 0 m MN a +
counterion containing buﬀer. In general, the highest DNA
destabilization eﬀect was seen when the monoadduct was
positioned between pyrimidine residues. Osmium tetroxide
(OsO4) and DEPC probing revealed that both thymine and
the opposite adenine are crucial for the local distortion of
the DNA structure by the platinum mono-adduct positioned
within a 5 -TGC triplet but not within a 5 -AGT or 5 -TGA
triplet. In contrast, none of these chemical probes reacted
withthebifunctional adductat the5 -TGGT sequence[110].
H¨ agerl¨ of et al. found that the cisplatin derivatives
cis-[P tCl(NH 3)2(OH2)]+, cis-[PtCl(NH3)(c-C6H11NH2)(OH2)] +,
and trans-[PtCl(NH3)(quinoline)(OH2)]+destabilized both
double-stranded DNA and double-stranded RNA (Figure 3).
Indeed, after platination with these compounds, the melting
temperatures for both the RNA and DNA hairpins fell. With
hairpin RNA, platination induced much weaker destabiliza-
tion, with a ΔTm of −5◦C. In the case of DNA, the platinum-
induced destabilization was more pronounced, with ΔTm
values of around −11◦C[ 111].
4.2.2. Ruthenium-Containing Alkylators. Transition-metal
antitumor agents other than platinum compounds also
present DNA unwinding activity. This is the case for ruthe-
nium derivatives such as [(η6-p-cymene)Ru(II)(en)-(Cl)]+
(Ru-CYM, Figure 4). This organometallic ruthenium(II)
arene complex was rationally designed on the basis that
changing the metal ion from platinum to ruthenium should
provide additional coordination sites in the octahedral
complexes, modify the oxidation rate, and change the ligand
aﬃnity and binding kinetics for use in chemotherapy [7,
112–114]. In particular, Brabec and co-workers performed
Tm studies while varying the drug/DNA ratio in buﬀer
containing NaClO4 concentrations ranging from 0.01M to
0.2M [115, 116]. ΔTm measurements at a drug/DNA ratio of
0.1 showed a decrease of up to 4◦C in the CT-DNA melting
temperature at all Na+ concentrations.
This DNA helix destabilization was also observed
usingbiphenyl(Ru-BIP),dihydroanthracene(Ru-DHA),and
tetrahydroanthracene (Ru-THA)( Figure 4)a sa r e n e sb u t
only at the highest concentration of NaClO4 [115]; at lower
Na+-counterion concentrations, Ru-BIP, Ru-DHA and Ru-
THA induced DNA helix stabilization, due to a positive
charge eﬀect on the ruthenium moiety and the intercalation
process. When compared with the other ruthenium arene
complexes, the DNA helix destabilization activity of Ru-
CYM correlates with a smaller unwinding angle of 7◦ (versus
14◦ of unwinding in supercoiled plasmid DNA by Ru-
BIP, Ru-DHA and Ru-THA). The Ru-CYM-induced DNA-
unwinding appears to be consistent with the absence of
intercalation of Ru-CYM between two adjacent base pairs
and the formation of monoadducts on the N7 atom of
guanine residues [116]. Ru-THA and Ru-CYM have been
used as models for the repair of DNA-ruthenium complexes
the compounds destabilize the DNA helix via diﬀerent
enthalpic eﬀects and diﬀer in terms of their DNA base-
pair intercalation propensity. DNA destabilization was also
recently evidenced for new ruthenium derivatives, such as
monodentate-Ru(II) [117].
4.2.3. Psoralen Derivatives. In terms of DNA stabiliza-
tion/destabilization properties, the psoralen derivative 4 -
(hydroxymethyl)-4, 5 ,8-trimethylpsoralen (HMT)( Figure 5)
exerts two eﬀects: (i) monoaddition of a psoralen residue
stabilizes the double helix formed by two non-self-
complementary oligonucleotides by as much as 1.3kcal/mol
(for a furan-side mono-adduct) or 0.7kcal/mol (for a
pyrone-side mono-adduct) at 25◦C in 50mM NaCl; (ii)
mono-addition of a psoralen residue to each of the two
thymidines in the double helix in the sequence GGGTACCC
destabilizes the helix by 1.8kcal/mol at 25◦Ci n1 MN a C l —
the two HMT molecules at the centre of each strand cause
an unfavourable enthalpy change and a favourable entropy
change [85].
4.2.4. Benzopyrene Carcinogens. In the cell, the environ-
mental and tobacco smoke carcinogen benzo[a]pyrene
(BaP) is metabolized into (+/−)-anti-benzo [a]pyrene-
7,8-dihydrodiol-9,10-epoxide (BPDE)( Figure 5). The (+)-
7R,8S,9S,10Renantiomer(+)-anti-BPDEisthoughttobethe
metabolite that is ultimately responsible for mutations, DNA
damage, and cancer. By covalently linking to the exocyclic
NH2 group of guanine, BPDE forms a bulky DNA adduct
in the minor groove of the helix and destabilizes base pairing
[120, 121].Journal of Nucleic Acids 7
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Figure 4: Ruthenium derivatives. Ru-CYM, Ru-BIP, Ru-DHA, and
Ru-THA are examples of ruthenium-containing agents inducing
local destabilization of the DNA helix.
Several enantiomers are produced by the alkylation
reaction which follows the opening of the epoxide group.
The (+)-anti-BPDE adducts consist mostly of the car-
cinogenic 10S (+)-trans-anti-BPDE (derived from the (+)-
7R,8S,9S,10R compound) and, to a lesser extent, stereoiso-
meric 10R (+)-cis-B [a]P-N2-dG adducts. The (−)-BPDE
enantiomer forms (−)-trans-B [a]P-N2-dG adducts but with
lower eﬃciency. The DNA bonding of the stereoisomeric
damage suggests base displaced intercalation or minor
groove conformations. Covalent adduct formation prevents
the amino group of guanine from hydrogen bonding with
the opposite cytosine (which otherwise stabilizes GC base
pairs in the native DNA helix). This results in base ﬂipping,
withthe(+)-anti-B[a]P-N2-dGbulkyadductontheguanine
situated in the minor groove and the opposite cytosine
aligned with the major groove [122, 123].
Depending on the target sequence, the bulky 10S (+)-
trans-anti-B [a]P-N2-dG rings point in the 5  direction
relative to the alkylated guanine position in each case,
although the exact positions are diﬀerent. Indeed, using 5 -
CGG∗C DNA, the 10S (+)-trans-anti-B [a]P-N2-dG lesion
untwists the DNA signiﬁcantly and causes a large bend in
the DNA helix. In contrast, with a 5 -CG∗GC sequence, no
untwisting is seen but the DNA helix is destabilized 5  to the
lesion [124]. These structural diﬀerences result in diﬀering
electrophoretic mobility in polyacrylamide gels and diﬀer-
ent protein/DNA recognition and DNA repair eﬃciencies
[125].
Although the BaPs are environmental mutagens and not
antitumoragents,theirveryparticularmodeofDNAbinding
with dual interference on DNA repair processes could
highlight useful phenomena involved in the mechanism of
action of cancer drugs (such as eﬀects on DNA repair, as
described in Section 5).
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Figure 5: Other DNA alkylating agents inducing local destabi-
lization of the DNA helix. (a) Structures of some DNA alkylating
molecules that destabilize the DNA helix. (b) Three-dimensional
organization of the psoralen derivative HMT (a) and (+)-anti-
BPDE (b) bound to DNA (crystallographic data [mmdbId:52343]
[118] and [mmdbId:52106], respectively, [119]).8 Journal of Nucleic Acids
4.2.5. 4-Hydroxyequilenin (4-OHEN). As is the case for
BaP, 4-OHEN alkylating agents are genotoxic but are
not anticancer drugs. 4-OHEN compounds are derived
from equine oestrogens (equilin, 3-hydroxy-1,3,5(10),7-
estratetren-17-one, and equilenin, 3-hydroxy-1,3,5(10),6,8-
estrapenten-17-one) which are present at various concen-
trations in the hormone substitution therapies used to
reduce the side eﬀects of the menopause but which are also
thought to contribute to a greater risk of breast cancer in
the treated population [126–128]. In the body, both equilin
and equilenin are rapidly converted into the intermediate
catechol 4-hydroxyequilenin, which is further oxidized into
the reactive 4-hydroxyequilenin-o-quinone (Figure 5)[ 129].
This ortho-quinone form of 4-OHEN is a potent cytotoxic
and genotoxic agent [130] and forms a bulky lesion on dA,
dC, and dG but not T residues [131–134]. This damage
can be detected not only in cell culture but also in breast
cancer biopsies from patients having undergone hormone
substitution therapy [135]. Each of the base adducts are
presentasfourstereoisomers,eachofwhichinducesdiﬀerent
levels of structural distortion in duplex DNA [136–138].
4-OHEN-C adducts present an unusual cyclic core with
the bulky rings pointing along the major or the minor
groove depending on whether the glycosidic bond adopts
a syn- or anticonformation, respectively [139]. Alkylation
of an 11-bp oligonucleotide at speciﬁc dA or dC residues
results in a strong decrease in the melting temperature of
the double-stranded DNA, compared with the unmodiﬁed
oligonucleotide. The magnitude of the decrease depends on
the position of the adduct within the oligonucleotide: a 6–
9◦Cd e c r e a s ei nTm is obtained when the adduct is located 1
or 2-bp from the end of the 11-bp DNA, whereas a large (21–
27◦C) decrease is induced when the adduct is present more
centrally (positions 4 to 8).
The extent of the destabilization also depends on the
adduct’s stereoisomeric orientation, as deﬁned using circular
dichroism measurements [134], thermodynamic analyses
and molecular modelling. Indeed, distortions, base-stacking
characteristics,andgroovesizeswerefoundtovaryaccording
to the nature and the stereoisomerism of the bulky DNA
lesion [139].
4.2.6.BenzoacronycineDerivatives. ThecompoundS23906-1
[(+)-cis-1,2-diacetoxy-6-methoxy-3,3,14-trimethyl-1,2,3-
14-tetrahydro-7H-benzo[b]pyrano[3,2-h]acridin-7-one]
(Figure 5) is a potent DNA-alkylating agent with strong
cytotoxic and antitumour properties. On the basis of very
promising preclinical trials, it entered clinical trials in 2006
(Servier, France). S23906-1 alkylates DNA on guanine’s
exocyclic amino group (located in the minor groove of
the DNA helix) and thus contrasts with commonly used
chemotherapeutic alkylating agents which react at guanine’s
N7 position in the major groove (cisplatin, nitrosourea,
nitrogen mustards, etc.). This nucleophilic point is also
targeted by other clinically used antitumour agents, such as
ecteinascidine-743 (ET-743/trabectedin/Yondelis) developed
by the company PharmaMar (Spain) [140], mitomycin-C (a
dual alkylating agent which bonds to either the N2 group of
guanine in the minor groove or the N7 group of guanine in
the major groove) [141]a n danthramycin [142].
In contrast to ET-743, mitomycin-C and the anthra-
mycins, the alkylation of double-stranded DNA by S23906-1
results in local destabilization of the DNA helix and thus
the formation of a single-stranded DNA portion that can be
attackedbysingle-strand-speciﬁcnucleases(suchasnuclease
S1) [91]. This destabilization was seen with various multiple
derivativesofS23906-1(e.g.,estersofthebenzo[b]acronycine
core, Figure 5). The dicarbamate derivative S29385-1 had a
very strong eﬀect. The DNA destabilization potency of this
series was conﬁrmed in a variety of physical and biochemical
approaches. For example, quantiﬁcation of the ratio between
the ﬂuorescence of Picogreen (a dye which interacts with
both double- and single-stranded DNA) and ethidium
bromide (BET) (a double-stranded-speciﬁc dye) revealed
additional Picogreen binding and suggested that S29385-1
generates single-strand DNA (Figure 6(a)). Accordingly,
DNA melting temperature studies evidenced a negative ΔTm
value, reﬂecting DNA destabilization (Figure 6(b)).
S23906-1’s ability to destabilize DNA was also clearly
demonstrated in biochemical approaches, such as elec-
trophoretic mobility shift assays (generating single-stranded
DNA form following alkylation of a fully double-stranded
DNA fragment) and the use of nuclease-S1 single-strand-
speciﬁcdigestiontomaptherelativepositionsoflocallyDNA
openings induced by alkylation (Figure 7 and [91]).
5. Drug-InducedDNA Destabilization:
CellularConsequences
Compounds which change the equilibrium between the
stable, double-stranded DNA helix and locally destabilized
strands could strongly alter protein/DNA recognition and
thus have major cellular consequences. Indeed, base kink-
ing, unstacking, and nucleotide extrusion (ﬂipping) induce
discontinuities in the double helix and thus facilitate DNA
lesion/mismatch recognition [143–145]. The few literature
studies to have addressed this point reveal that proteins
which recognize damaged DNA are aﬀected by the stabi-
lization or destabilization of the DNA helix; this leads to a
m a j o ri m p a c to nb i o l o g i c a lp a r a m e t e r ss u c ha sa n t i t u m o u r
activity, transcription factor binding potency, and DNA
repair process eﬃciency [146–148].
This type of cellular impact has been particularly well
demonstratedfortheplatinatedadductsrecognizedbyHMG
proteins [149]. HMG/platinated DNA recognition is trig-
geredbythestrongDNAbendinggeneratedbytheplatinated
agent (Figure 2). The large induced bend ﬁts perfectly with
the L-shaped structure of HMG DNA binding domain
(HMG-box) and reduces the “cost” of DNA bending for the
protein [150]. As a consequence, HMG proteins bind less
well to oxaliplatin adducts than to cisplatin adducts because
the former agent induces relatively greater DNA bending
and thus stronger DNA destabilization [151]. This ﬁnding
correlates with the lower level of DNA lesions found in cells
treated with oxaliplatin,r e l a t i v et ocisplatin.I ti sa s s u m e d
thatHMGbindingshieldstheplatinatedadductsfromrepairJournal of Nucleic Acids 9
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Figure 6: DNA destabilization propensities of the benzo-
acronycine dicarbamate derivative S29385-1.( a )C T - D N Aw a s
incubated with increasing concentrations of S29385-1 prior to
the incubation with a mixture of ethidium bromide (BET)a n d
Picogreen (PG from Molecular Probes, Invitrogen) to quantify only
double-strand DNA or both double-strand and single-stranded
DNA, respectively. Results are expressed as the percentage of the
peak of emission for BET versus PG. (b) Variation of the melting
temperature studies of a short 24-bp double-strand oligonucleotide
incubated for 24 hours alone or with increasing concentrations
of S29385-1 prior to ethanol precipitation of the sample and
melting temperature measurement. The results are expressed as
the melting temperature for the [DNA+drug] complex minus
melting temperature for DNA alone. (Details for the corresponding
experimental protocols are described in [91].)
by the human DNA excision machinery [152] and therefore
participates in platinated-agent-induced cytotoxicity [153].
However, too strong a bend and greater DNA destabilization
lead to a structure that does not ﬁt perfectly with L-shaped
HMG-box, thus resulting in a weaker HMG protein binding.
TheweakerHMGbindingtooxaliplatin adductscorresponds
to weaker protection from DNA repair and so oxaliplatin-
DNA lesions are more eﬃciently repaired than cisplatin-
induced lesions. This results in a lower number of lesions
in cells for oxaliplatin than for cisplatin.M o r e o v e r ,b e n t
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Figure 7: Nuclease S1 mapping of locally opened DNA structure.
Increasing concentrations of the benzo-b-acronycine derivatives
presented in Figure 5 were incubated with a radio-labelled 117-
bp DNA fragment prior to subjection to nuclease S1 mapping
of the induced locally single-stranded DNA portions generated
upon DNA alkylation. DNA samples were separated on a 10%
nativepolyacrylamidegel.ConcentrationsareexpressedinμM.The
detailed experimental protocol is described in [91].
platinated-DNA is a good substrate for transcription factors
such as SRY and LEF-1 (which belong to the HMG-box
family, regarding their DNA-binding domain) and explains
the observation of transcriptional changes in treated cells
[92, 154–156].
Regarding DNA repair, the local destabilization of the
double helix, base ﬂipping and poor base stacking all
play a role in the recognition of DNA lesions by repair
proteins [157–160]. This has been well demonstrated for the
MSH2/MSH6heterodimermismatchrepaircomplex(Mut-S
alpha), which recognizes not only mismatched bases but also
certain DNA lesions, such as cisplatin (but not transplatin)
crosslinks [161–165].
In the case of ruthenium-derivative-induced DNA
lesions, the NER machinery appears to be less eﬃcient than
forplatinumadducts.Interestingly,Ru-CYM adducts(which
destabilizetheDNAhelixmuchmorethanRu-THA adducts)
are excised more eﬃciently than Ru-THA complex adducts.
This is consistent with the lower binding by RPA to DNA10 Journal of Nucleic Acids
containing Ru-THA adducts and (to a lesser extent) Ru-
CYM/DNAdamage[166].TheobservationthatRu-THA was
much more cytotoxic than Ru-CYM in both A2780 human
ovarian cancer cells and the HT29 colon carcinoma cell line
suggests that DNA intercalation has a major role in the
cytotoxicity of these DNA-destabilizing derivatives.
In prokaryotes, the NER sensor protein UvrB eﬃciently
recognizesBaP lesionsthroughlesion-induced localthermo-
dynamic distortion/destabilization and nucleotide ﬂipping
[167]. Some variations in the excision eﬃciency (up to a
factor of 3-fold) are observed, depending on the stereoiso-
meric orientation of the DNA adducts (i.e., (+) or (−), cis-
or trans-) [121]. In eukaryotes, the BaP lesions are usually
recognized by the NER machinery’s “sensor” protein XPC,
which then initiates DNA repair in association with the
HR23B protein [168, 169]. In particular, it has been sug-
gested that XPC/HR23B’s weaker recognition of (+)-trans-
B [a]P-N2-dG adducts (relative to the other conformers)
contributes to its higher mutagenic and tumorigenic activity
[168]. XPC binding requires DNA bending [170] and is
facilitated by local conformational ﬂexibility [143, 144, 171]
and destabilization of the base pairing, as evidenced by
several model DNA lesions (such as thymine-glycol) [172].
This recognition is driven by the “aromatic sensors” Trp690
and Thp733 [41]. On the cellular level, human bronchial
epithelial 16HBE cells treated with BaP (as a source of
reactive BPDE) displayed greater expression of the NER
proteins XPA and XPG and the heat shock protein Hsp70.
Subcellular analysis with confocal microscopy evidenced
nuclearcolocalizationofHsp70withXPAandXPGafterBaP
treatment, suggesting that Hsp70 has a role in the cellular
DNA repair response [173]. Accordingly, (+/−)-anti-BPDE
induces chromosome instability and centromere ampliﬁca-
tion in lung cells [174]. The cellular consequences of (+/−)-
anti-BPDE treatment were also assessed using a whole-
genome microarray technique in normal human amnion
epithelial cells; the researchers observed downregulation of
the expression of genes involved in signal transduction,
cytoskeleton, DNA repair, metabolism and regulation of
transcription and the cell cycle, with features similar to those
observed after cell irradiation with UV-light [175, 176].
It was recently reported that the structural diﬀerences
observed for an identical, highly mutagenic, (+)-(7R,8S,
9S,10R)-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo
[a]pyrene-DNA lesion lead to diﬀerent repair processes as
a function to the sequence contexts. Indeed, in cell-free
human HeLa extracts, destabilized DNA at a 5 -CG∗GC
site was more rapidly excised than the bent DNA at a
5 -CGG∗Cs i t e[ 125]. Since the DNA helix is already opened
up by alkylation, the DNA repair protein recognition step
(including induced base ﬂipping) requires less energy and
thus is potentially more rapid for DNA that has already
been destabilized (at a 5 -CG∗GC site) than for bent duplex
DNA (the 5 -CGG∗C site). This study clearly emphasized
the importance of the DNA sequence context for eﬃcient
adduct repair [177].
Isomer-dependant DNA repair potency is also assumed
to occur with bulky catechol 4-OHEN-adducts, which NER
proteins excise with an eﬃciency that depends on the
alkylated base, the stereoisomerism of the adducts and the
sequence context. For example, 4-OHEN-dC adducts are
more eﬃciently excised than 4-OHEN-dA adducts [178].
Interestingly, it was shown in male zebraﬁsh that 17a-
ethinylestradiol (a source of 4-OHEN)i sa b l et od e c r e a s e
NEReﬃciencyandtheexpressionofNERgenessuchasXPC,
XPA, XPD, and XPF (but not HR23B) [179, 180].
In the search for new cancer drugs with novel mecha-
nisms of action and on the basis of promising preclinical
testing, the benzoacronycine derivative S23906-1 has entered
Phase I clinical trials as a racemate of two cis-diacetylated-
enantiomers. As mentioned above, S23906-1 alkylates DNA
in the minor groove and induces strong destabilization of
the double helix. Given the presence of two reactive acetate
groups on asymmetric carbons, two pairs of enantiomers
can be formed: two cis (1R; 2R and 1S; 2S) and two trans
(1R; 2S and 1S; 2R)s t r u c t u r e s .H e n c e ,S23906-1 is a mixture
of 1R; 2R and 1S; 2S. We tested the ability of each of the
pure cis-enantiomers not only to react with DNA but also
to destabilize the DNA helix and thus aﬀect single-stranded
endonuclease activity [181]. Our results showed that DNA
destabilization depends on the orientation of the adduct core
in the open drug/DNA complex and correlates with diﬀering
cellular and antitumour eﬀects: the enantiomer with the
greatestDNAdestabilizationpresentsthehighestantitumour
activity in animal models [181].
Little is known about the repair of S23906-1 DNA
adducts: the involvement of the NER proteins XPC and
CSB was recently found to be related to cell sensitivity to
S23906-1, associated with both global genome repair and
transcription coupled NER [182].
Ongoing work is seeking to identify the proteins involved
in S23906-1/DNA adduct recognition and evaluate their
impact on the compound’s cytotoxic activity. On one hand,
locally destabilized DNA could favour the recognition of a
DNA lesion by the DNA repair “sensor” proteins, leading to
an increase in the excision eﬃciency or rate. Full repair after
excision thus results in weaker antitumor activity, unless the
DNA repair process is blocked—as has been evidenced for
the antitumour activity of ET-743 (Yondelis). In this latter
case, the ET-743/DNA adduct traps the XPG endonuclease
protein involved in the NER machinery and increases the
number of single-strand breaks [183]. On the other hand,
the wide, local opening of the DNA helix prompted by
this particular compound may increase cleavage by single-
strand-speciﬁc nuclear endonucleases; the greater number of
double-strand breaks may then overwhelm the cancer cells’
DNA repair capacity.
6. Conclusions
Drug-induced destabilization of the DNA helix appears to be
part of a novel antitumour mechanism of action and is asso-
ciated with particular intercalation processes or postalky-
lation DNA distortions. DNA-destabilizing compounds are
relatively rare and represent just a few drops in an ocean
of DNA-interacting molecules (which primarily stabilize the
double helix). The molecular and cellular consequences ofJournal of Nucleic Acids 11
this original binding mode diﬀer from those induced by
DNA-stabilizing compounds. In particular, DNA repair and
transcription processes are now known to be aﬀected. The
DNA replication machinery may also be aﬀected because
DNA opening requires less energy when the double helix is
already destabilized by a drug. In view of the little available
literature data, researchers are now starting to ﬁll in this
gap.
Furthermore, we believe that it is important not to
consider DNA destabilization as a unique process. This
phenomenonmustbeconsideredinrelationto(i)thepoten-
tially associated bend in the DNA helix (as evidenced by
the comparison between oxaliplatin-a n dcisplatin-induced
distortions of DNA [151] or the eﬀect of the diﬀerent
isomers of BPDE [125, 177]), and (ii) the length of the
locally destabilized DNA, which varies according to the
compound’s nature (i.e., the DNA opening induced by
benzoacronycine derivatives appears to be extensive enough
to be susceptible to single-strand-speciﬁc nucleases, whereas
other modiﬁcations are not) [91]. Recent and ongoing
studies of the impact of DNA destabilization on DNA repair
and cytotoxicity activities illustrate the increasing need for
accurate determination of a potential cancer drug’s DNA
binding mode and subsequent cellular eﬀects. Moreover,
DNA-destabilizing compounds may be associated with dif-
ferent drug-induced resistance processes. Further knowledge
of three-dimensional structure activity relationships and the
cellularconsequences(cytotoxicity,DNArepairprocesses)of
treatment with DNA-destabilizing agents will help to clarify
the relevance of cancer drug candidates which stabilize or
destabilize the DNA helix and will aid the design of potent
antitumour agents.
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